B+
Bull case
25%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
MRK
MerckBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 release supports a cautiously constructive thesis: sales grew 5%, KEYTRUDA QLEX and WINREVAIR contributed to growth, FY sales guidance was raised, and LIPFENDRA plus oncology and HIV milestones broaden the portfolio. The company also has multiple future clinical and regulatory value drivers.
Posture
Constructive
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-10-29.
What can break
LIPFENDRA commercial uptake and the contribution from newer launches are not yet demonstrated in the supplied operating data.
Momentum
80
Value
61
Sentiment
56
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $136.72 · Bull $145.00 · Bear $115.00Analysis 2026-08-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $158.84
Why
Momentum80 · Δ7d -26.9
Value61 · Δ7d +0.2
Sentiment56 · Δ7d +5.6
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-29.
- • Value remains the lead driver in the composite, 7D delta +0.2.
Contradictions & invalidation
- • LIPFENDRA commercial uptake and the contribution from newer launches are not yet demonstrated in the supplied operating data.
- • Positive clinical and regulatory milestones do not guarantee approval, launch execution, or durable commercial revenue.
- • The headline EPS profile is distorted by the Terns acquisition, with $2.31 per share of Q2 charges and $2.43 per share of FY2026 charges.
Catalyst clock
2026-07-16
LIPFENDRA FDA approval milestone
Lead driver: Value · See fundamentals
Momentum
80
8% active weight
Current posture
7d trendSoftening
Δ7d
-26.9
Δ21d
-16.0
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.5
Sentiment
56
45% active weight
Current posture
7d trendImproving
Δ7d
+5.6
Δ21d
-4.8
Why this grade
Composite grade B. Momentum 79.7 / Value 60.9 / Sentiment 55.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-07. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$136.72
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$115.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$361.02B
Beta
0.29
Shares Out
2.47B
P/E (TTM)
14.2
P/S (TTM)
4.15
P/FCF (TTM)
53.98
Rev YoY
+4.9%
EPS YoY
-130.7%
Gross Margin
+72.4%
Op Margin
+18.8%
Net Debt
$35.84B
Current Ratio
1.32
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data